IQVIA Holdings Inc. — Q3 2023 Form 10-Q
Business context and period. IQVIA provides analytics, technology and clinical research services to the life sciences industry. This unaudited report covers the three and nine months ended September 30, 2023; comparisons are with the corresponding 2022 periods. Amounts are in millions of dollars except per-share data.
Key financial results
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $3,736 | $3,562 | $11,116 | $10,671 |
| Income from operations | $481 | $472 | $1,476 | $1,420 |
| Net income | $303 | $283 | $889 | $864 |
| Diluted EPS | $1.63 | $1.49 | $4.76 | $4.52 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $1,402 | $1,700 |
- Q3 revenue increased 4.9% reported and approximately 4.1% at constant currency; nine-month revenue rose 4.2% reported and approximately 4.8% at constant currency.
- Q3 operating margin was approximately 12.9%, versus 13.3% a year earlier; cost of revenues was 64.9% of revenue versus 65.2%. Nine-month cost-of-revenue ratio was 65.4% in both years.
- At September 30, cash was $1,224; current assets were $5,208 and current liabilities $6,589. Principal debt was $13,689, including $1,309 current; additional revolving-credit capacity was $1,745. The company reported compliance in all material respects with financial covenants.
- Nine-month cash used in investing was $1,391, including $869 for acquisitions and $470 for property, equipment and software. Financing provided $38; share repurchases were $763.
Changes and segment performance
- Research & Development Solutions drove growth: Q3 revenue rose 7.2% to $2,122 and segment profit rose 11.2% to $495. Nine-month revenue increased 6.5% to $6,244 and segment profit rose 11.8% to $1,391.
- Technology & Analytics Solutions Q3 revenue grew 2.2% to $1,431, while segment profit declined 1.1% to $355. Nine-month revenue grew 2.0% to $4,331, while profit fell 3.8% to $1,086.
- Contract Sales & Medical Solutions Q3 revenue was unchanged at $183; nine-month revenue declined 3.6% to $541. Segment profit increased in both periods.
- Interest expense rose to $181 in Q3 from $108 and to $491 for nine months from $288, primarily due to higher base rates on floating-rate debt and increased net debt. Operating cash flow fell $298 year over year for the first nine months, reflecting working-capital and other operating-cash changes.
Outlook, risks and unusual items
- The filing provides no explicit full-year revenue or earnings guidance. Management said available cash, expected operating cash flows and access to credit facilities should fund operations, capital expenditures, contractual obligations and debt service for at least the next 12 months.
- Research & Development Solutions contracted backlog was $28.8 billion at September 30, up from $27.2 billion at year-end 2022; approximately $7.4 billion was expected to convert to revenue over the next 12 months. Separately, remaining performance obligations were approximately $31.3 billion, with about 30% expected to be recognized within 12 months and 85% within five years; this measure excludes certain cancellable, wholly unperformed contracts.
- Restructuring costs were $30 in Q3 and $67 for nine months, versus $4 and $15, respectively, in 2022. Actions to streamline operations and integrate acquisitions are expected to continue through 2023 and into 2024.
- The 2023 effective tax rate benefited from a $21 reversal of uncertain tax positions. Management said anticipated legal-entity restructuring could permit use of foreign tax credits and may produce a material discrete tax benefit.
- Key disclosed risks include client contract termination or delays, data privacy and security, foreign exchange, interest rates, backlog conversion, acquisitions and litigation. The company said pending legal and tax matters are not expected to have a material adverse effect overall, while noting outcomes could differ; Veeva counterclaims seek damages exceeding $200.
Important facts for investors to verify
- Whether clinical-research growth and backlog conversion support continued revenue and segment-profit growth.
- How higher borrowing costs and upcoming maturities affect interest expense, refinancing needs and liquidity.
- Whether working-capital trends—particularly unbilled services and receivables—improve and support cash generation.
- The timing and cash cost of restructuring, acquisitions and authorized share repurchases; remaining repurchase authorization was $2,592 at quarter-end.
- The realized effect of the anticipated foreign-tax-credit valuation-allowance reversal and the eventual outcomes of significant litigation.